Company intelligence / Profile preview
MiNK Therapeutics
New York, New York, United Statesminktherapeutics.com ↗
- Ownership
- Public · INKT
- Employees
- ~23
- Development stage
- Phase 2
01
Overview
Currently in Phase 2 clinical trial for the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma. Also in Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors for refractory solid tumor cancers, and Phase 1 trial for viral acute respiratory distress syndrome.
- Therapeutic areas
- OncologyPulmonologyImmunology
- Modalities
- Allogeneic invariant natural killer T (iNKT) cell therapiesCAR-iNKTTCR therapies
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Autonomous TherapeuticsImmunoScape, Inc.
04
Financials
- Market cap
- $59.3M
- Total revenue
- $0
- Enterprise value
- $50.5M
Beyond the preview
Go deeper on MiNK Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MiNK Therapeutics.